Ichiro (Paul) Mori
President and Chief Executive Officer
Paul Mori is co-founder, President and Chief Executive Officer of Teikoku Pharma USA (TPU) established in 1997. Mr. Mori brings over 35 years of international pharmaceutical business experience. While at TPU, he has established partnerships with major and mid-sized Pharmaceutical companies — among them Becton Dickinson, Bristol-Myers Squibb, Endo Pharmaceuticals, Grunenthal and Mundi Pharma etc. Prior to joining TPU, Mr. Mori worked for Alpha Therapeutic Corporation in Los Angeles, California as Associate Director of International Regulatory Affairs. While at Alpha he was involved in various product registrations of pharmaceutical/biological products in over 20 countries. Prior to Alpha Therapeutics Corporation, Mr. Mori held was an international operations manager for Green Cross Corporation (now Mitsubishi Tanabe Pharma) in Osaka, Japan. There, he was involved in Fluosol and Soyacal NDA approvals. Mr. Mori also serves as Chairman/Vice Chairman for JPMA-WEST (Japanese pharmaceutical industry association, US West coast region, voluntary organization). Mr. Mori received his bachelor’s degree from Kobe University in 1981.
Executive Vice President & Chief Financial Officer
Atsumu Matsushita joined Teikoku Pharma USA (TPU) in 2000 and currently serves as the Exec. VP & CFO. His responsibilities also include general affairs, and acting head of HR, Legal and Purchasing. Prior to joining TPU Mr. Matsushita served as the accounting manager for Teikoku Seiyaku Co., Ltd. (TSC) in Japan. During his tenure at TSC, he held various positions of increased responsibilities, starting as a sales representative and eventually becoming deputy manager of accounting. Mr. Matsushita received his bachelor’s degree in Economics from Kokugakuin University in Tokyo, Japan.
Jutaro Shudo, PhD
Vice President, Scientific Advisor & Liaison
Jutaro Shudo joined Teikoku Pharma USA (TPU) in 2000. Dr. Shudo currently serves as Vice President of Scientific Advisor and Liaison. Before joining TPU, Dr. Shudo worked at Teikoku Seiyaku Co., LTD as a formulation scientist for the drug and cosmetic division. Dr. Shudo has been instrumental in the development of our chemotherapy drug and also headed the development of our Alzheimer drug in collaboration with Eisai. In his 20 year career, he has contributed to not only R&D, but Regulatory and Clinical efforts as well. His expertise also includes scale-up manufacturing. Dr. Shudo received a PhD in Pharmaceutical Science from Chiba University in Japan.
Vice President, Licensing and Strategic Alliances
Francisco Bejar joined Teikoku Pharma USA (TPU) in 1999 and currently serves as Vice President of Licensing and Strategic Alliances where he is tasked with leading the corporate strategy, as well as executing in- and-out licensing transactions. During this time Mr. Bejar has held a variety of positions with increasing responsibilities most recently as Sr. Director of Business Development where he has been responsible for a number of significant partnerships including leading M&A transactions. Prior to TPU, Mr. Bejar worked for Cell Genesys Biotech and Oread Pharmaceuticals gaining significant drug development experience and contributing to the growth of the companies. He has more than 21 years of experience as a successful executive in the pharmaceutical and biotech field. Mr. Bejar received a bachelor’s degree in Biophysics from La Sierra University in Riverside, CA.
Vice President, Business Development and Operations
In his role, Hiro Sakamoto oversees business operations at Teikoku Pharma USA (TPU) including supply chain, intellectual properties and international regulatory matters. Prior to joining TPU, Mr. Sakamoto worked for ITX International holdings Inc. an Olympus group company, with extensive experience in cross border business development and venture capital/ private equity investment in both Healthcare and Technology industries. Mr. Sakamoto received his Master of Business Administration from San Francisco State University and bachelor’s degree in Law from Nihon University.
James Song, MBA, MS
Vice President, Clinical, Regulatory and Project Management
James Song joined Teikoku Pharma USA (TPU) in 2008 and currently serves as Vice President Clinical, Regulatory and Project Management. Mr. Song brings over 30 years of clinical development experience with primary focus on anti-cancer, central nervous system, and transdermal delivery systems. During his time at TPU, Mr. Song has demonstrated strong leadership in the overall aspects of clinical development and has held various positions of increased responsibilities, most recently as Sr. Director of Biometrics and Clinical Affairs. Mr. Song was instrumental in the clinical development of a product for Alzheimer’s disease, working in collaboration with Eisai. Prior to joining TPU, Mr. Song worked for Solvay Pharmaceuticals, Matrix Pharmaceuticals, Alza Corporation (a Johnson & Johnson company) and Elan Pharmaceuticals. Mr. Song received a bachelor’s degree in Business Administration and a Master of Business Administration from Oklahoma City University and a Master of Science from Georgia State University.
Jack Wen, PhD
Vice President, CMC, Quality, Non-Clinical
Jack Wen joined Teikoku Pharma USA (TPU) in 2007 and currently serves as Vice President of CMC/Quality/Non-Clinical. During his time at TPU, Dr. Wen has held a variety of positions with responsibilities ranging from new product development to commercial contract manufacturing. Prior to his time at TPU, Dr. Wen worked for Alza Corporation with extensive experience in drug delivery technology, particularly transdermal drug delivery. He has authored many papers, book chapters, and patents. Dr. Wen received his PhD in Chemistry from the University of Cincinnati.